Loading
CB
China Biotech Services Holdings Ltd. Stock: price and insider trades · Hong Kong
1 insider bought €2,764 of shares over the last 90 days, the latest by Liu Xiaolin, filed 21 Oct 2026.
China Biotech Services Holdings Ltd.: what insiders have been doing
This page follows insider dealings at China Biotech Services Holdings Ltd. as filed with HKEX, a company from the Health Care sector. Over the twelve months to 21 October 2026, 3 filings were filed, from 1 insider.
Only purchases show up on the open market, 2 purchases in all worth €2,764, filed by 1 insider. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 senior executive. Liu Xiaolin filed the largest purchase, €2,764, on 21 October 2026.
The clock since the last published purchase (21 October 2026) now reads 4 days. Between a trade and the moment it shows up on HKEX, the median delay is 3 days. That lag is the time during which only the insider knows about the trade.
Compared with its exchange (1,314 companies, median 4 filings), a count of 3 filings is below the norm. The full history, which starts in 2017, counts 27 purchases against 24 sales.
This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€13M
27 ops. · all time
Sell Volume
€41M
24 ops. · all time
Who traded when
BuySaleLiu Xiaolin2 buys
Since the insiders bought
- +86.3%Entry HK$0.37 · Close at T+365 HK$0.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,803 of 26,290 companies
9.2
score / 100
Value10
Quality9
FCF yld-37%
Earn yld-13%
EV/EBITDA·
ROE-15%
Gross mgn11%
Net mgn-94%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$0.51
Analyst consensus
Income statement
RevenueHK$73.5M
Gross profitHK$7.7M11% margin
EBITDA-HK$45.8M-62% margin
Net income-HK$68.8M-21.6% margin
Valuation
P/Book2.3x
Beta-0.69
Balance sheet & cash
Market capHK$495.3M
Total debtHK$394.9M
Free Cash Flow-HK$191.4M
Debt / Equity245%
Profitability & ownership
ROE-15.0%
ROA-8.5%
% insiders64.5%
% institutions0.0%
Last declaration on 21 October 2026
Declarations67 total
45,000 shares@ HK$0.5406ShareXHKGHKEX:DA20261020E00468
Canonical exit: 13 Jan 2027 (T+90)
3,600,000 shares0ShareXHKGHKEX:DA20260402E00019
Canonical exit: 28 Jun 2026 (T+90)
410,000,000 sharesShareXHKGHKEX:DA20260205E00060
187,903,805 sharesShareXHKGHKEX:DA20241112E00397
3,220,000 sharesShareXHKGHKEX:DA20240905E00067
12,500,000 sharesShareXHKGHKEX:DA20240724E00350
12,500,000 shares@ HK$0.400.8% of flowShareXHKGHKEX:DA20240724E00353
12,500,000 shares@ HK$0.400.8% of flowShareXHKGHKEX:DA20240724E00351
Canonical exit: 18 Oct 2024 (T+90)
5,000,000 sharesShareXHKGHKEX:DA20240618E00049
30,000 shares@ HK$0.700.0% of flowShareXHKGHKEX:DA20240119E00426
Canonical exit: 18 Apr 2024 (T+90)
95,000 shares@ HK$0.67260.0% of flowShareXHKGHKEX:DA20240119E00423
Canonical exit: 17 Apr 2024 (T+90)
50,000 shares@ HK$0.7080.0% of flowShareXHKGHKEX:DA20240102E00290
Canonical exit: 28 Dec 2023 (T+90)
95,000 shares@ HK$0.68370.0% of flowShareXHKGHKEX:DA20240102E00287
Canonical exit: 27 Dec 2023 (T+90)
30,000 shares@ HK$0.600.0% of flowShareXHKGHKEX:DA20240102E00285
Canonical exit: 26 Dec 2023 (T+90)
292,000 sharesShareXHKGHKEX:DA20230919E00302
Canonical exit: 14 Dec 2023 (T+90)
3,220,000 sharesShareXHKGHKEX:DA20230904E00213
320,000 sharesShareXHKGHKEX:DA20230823E00176
10,000 shares@ HK$0.870.0% of flowShareXHKGHKEX:DA20230710E00349
Canonical exit: 4 Oct 2023 (T+90)
10,000 shares@ HK$0.890.0% of flowShareXHKGHKEX:DA20230706E00329
Canonical exit: 3 Oct 2023 (T+90)
100,000 shares@ HK$0.8080.0% of flowShareXHKGHKEX:DA20230706E00328
Canonical exit: 2 Oct 2023 (T+90)
130,000 shares@ HK$0.80460.0% of flowShareXHKGHKEX:DA20230706E00327
Canonical exit: 1 Oct 2023 (T+90)
140,000 shares@ HK$0.99250.0% of flowShareXHKGHKEX:DA20230531E00335
Canonical exit: 28 Aug 2023 (T+90)
110,000 shares@ HK$0.9550.0% of flowShareXHKGHKEX:DA20230531E00333
Canonical exit: 23 Aug 2023 (T+90)
5,000,000 sharesShareXHKGHKEX:DA20230113E00086
Canonical exit: 6 Apr 2023 (T+90)
264,750,273 sharesShareXHKGHKEX:DA20230104E00611
25 of 67 declarations
About China Biotech Services Holdings Ltd.
China Biotech Services Holdings Ltd. is a company specializing in biopharmaceutical services in China. It provides solutions for drug development and clinical research.
